Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 1;64(6):3266-3279.
doi: 10.1093/rheumatology/keaf064.

The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review

Alberto Ezquerra-Durán  1 , Luis G Alcala-Gonzalez  2   3 , Alfredo Guillen-Del-Castillo  4 , Carmen P Simeón-Aznar  4 , Elizabeth Barba  1 , Carolina Malagelada  2   3   5 , Michael Hughes  6   7 , Zsuzsanna H McMahan  8
Affiliations

The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review

Alberto Ezquerra-Durán et al. Rheumatology (Oxford). .

Abstract

Objectives: Gastrointestinal involvement (GI) in SSc is frequent and heterogeneous, manifesting with different degrees of dysmotility. This systematic literature review aimed to summarize evidence on prokinetics for treating SSc-related GI dysmotility.

Methods: Studies investigating the effects of prokinetic agents on GI function and/or GI symptoms in patients with SSc were systematically identified on PubMed and Embase. A qualitative data synthesis was conducted, given the (anticipated) wide heterogeneity in study designs, interventions and outcomes.

Results: Twenty-one studies evaluating the effects of prokinetics in patients with SSc were included. Thirteen studies focused on GI motility using objective tests, eight assessed clinical responses, and six evaluated both. Cisapride (n = 5 studies), metoclopramide (n = 7 studies), octreotide (n = 4 studies) and prucalopride (n = 1 study) were among the most studied prokinetics, with varying effects on different GI anatomical regions. While metoclopramide consistently improved overall GI motility, other prokinetics provided selective benefits; cisapride improved gastric emptying and colonic motility, but not oesophageal motility, and octreotide improved small bowel motility but delayed gastric emptying. Regarding symptomatic improvement, only prucalopride was evaluated using a validated patient questionnaire, showing improvement in both upper and lower GI symptoms.

Conclusion: Prokinetic drugs may improve GI motility and symptoms in patients with SSc. There is an unmet need for future well-designed studies to refine patient stratification and optimize treatment outcomes.

Keywords: gastrointestinal; prokinetics; scleroderma; systematic review; systemic sclerosis.

PubMed Disclaimer

References

    1. Pope JE, Denton CP, Johnson SR et al. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol 2023;19:212–26. doi: 10.1038/s41584-023-00909-5 - DOI - PMC - PubMed
    1. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437–44. doi: 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U - DOI - PubMed
    1. Roberts CGP, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 2006;55:1697–703. doi: 10.1136/gut.2005.086074 - DOI - PMC - PubMed
    1. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428–40. doi: 10.1016/0002-9343(69)90044-8 - DOI - PubMed
    1. Manetti M, Milia AF, Benelli G et al. The gastric wall in systemic sclerosis patients: a morphological study. Ital J Anat Embryol Arch Ital Anat Ed Embriologia 2010;115:115–21. - PubMed

Publication types

MeSH terms